VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas

PURPOSE: Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are being used for the first-line treatment of metastatic clear cell renal cell carcinoma (mccRCC). Here, we set out to explore associations between genomic statuses, gene expression clusters and clinical ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiale, Wang, Junyun, Kong, Wen, Zhang, Jin, Wu, Xiaorong, Huang, Jiwei, Zheng, Junhua, Chen, Yonghui, Zhai, Wei, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424144/
https://www.ncbi.nlm.nih.gov/pubmed/35834099
http://dx.doi.org/10.1007/s13402-022-00691-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424144/
https://www.ncbi.nlm.nih.gov/pubmed/35834099
http://dx.doi.org/10.1007/s13402-022-00691-8

Ejemplares similares